A detailed history of Tower Research Capital LLC (Trc) transactions in Protara Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 2,783 shares of TARA stock, worth $6,373. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,783
Previous 4,019 30.75%
Holding current value
$6,373
Previous $8,000 37.5%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.7 - $2.4 $2,101 - $2,966
-1,236 Reduced 30.75%
2,783 $5,000
Q2 2024

Aug 13, 2024

BUY
$1.96 - $4.14 $2,820 - $5,957
1,439 Added 55.78%
4,019 $8,000
Q1 2024

May 15, 2024

SELL
$1.86 - $4.83 $3,269 - $8,491
-1,758 Reduced 40.53%
2,580 $10,000
Q4 2023

Feb 13, 2024

SELL
$1.12 - $1.93 $510 - $880
-456 Reduced 9.51%
4,338 $8,000
Q3 2023

Nov 14, 2023

BUY
$1.64 - $2.93 $4,236 - $7,568
2,583 Added 116.82%
4,794 $8,000
Q2 2023

Aug 14, 2023

BUY
$2.27 - $3.59 $5,018 - $7,937
2,211 New
2,211 $5,000
Q4 2022

Feb 10, 2023

BUY
$2.43 - $3.7 $323 - $492
133 New
133 $0
Q2 2022

Aug 15, 2022

BUY
$2.8 - $5.33 $5,059 - $9,631
1,807 New
1,807 $5,000
Q1 2022

May 12, 2022

SELL
$4.19 - $6.9 $3,347 - $5,513
-799 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$6.15 - $7.76 $4,913 - $6,200
799 New
799 $6,000
Q3 2021

Nov 15, 2021

SELL
$6.38 - $9.3 $9,876 - $14,396
-1,548 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$8.68 - $16.99 $1,562 - $3,058
-180 Reduced 10.42%
1,548 $15,000
Q1 2021

May 17, 2021

BUY
$13.75 - $23.86 $8,332 - $14,459
606 Added 54.01%
1,728 $27,000
Q4 2020

Feb 16, 2021

SELL
$16.97 - $25.34 $11,980 - $17,890
-706 Reduced 38.62%
1,122 $27,000
Q3 2020

Nov 16, 2020

BUY
$16.76 - $31.89 $29,095 - $55,361
1,736 Added 1886.96%
1,828 $31,000
Q2 2020

Aug 13, 2020

BUY
$22.0 - $60.7 $2,024 - $5,584
92 New
92 $3,000

Others Institutions Holding TARA

About Protara Therapeutics, Inc.


  • Ticker TARA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 11,267,400
  • Market Cap $25.8M
  • Description
  • Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chlorid...
More about TARA
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.